Home
/
Vistagen Therapeutics, Inc.
/
Financials
/
Quarterly
Vistagen Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Vistagen Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2021
Jun 30, 2021
$354.1K
Aug 12, 2021
Q3
2021
Dec 31, 2020
$313.6K
Feb 11, 2021
Q2
2021
Sep 30, 2020
$334.0K
Nov 12, 2020
Q1
2021
Jun 30, 2020
$0
Aug 12, 2021
Q3
2021
Dec 31, 2019
$0
Feb 11, 2021
Q2
2021
Sep 30, 2019
$0
Nov 12, 2020
Q3
2018
Dec 31, 2017
$0
Feb 12, 2018
Q3
2018
Dec 31, 2016
$1.25M
Feb 12, 2018
Q3
2016
Dec 31, 2015
$0
Feb 13, 2017
Q3
2013
Dec 31, 2013
$16.37M
Feb 14, 2014
Q2
2013
Sep 30, 2013
$16.37M
Nov 14, 2013
Q1
2013
Jun 30, 2013
$16.37M
Aug 14, 2013
Q3
2013
Dec 31, 2012
$200.4K
Feb 14, 2014
Q2
2013
Sep 30, 2012
$200.4K
Nov 14, 2013
Q1
2013
Jun 30, 2012
$200.4K
Aug 14, 2013
Q3
2012
Dec 31, 2011
$2.4K
Feb 14, 2013
Q2
2012
Sep 30, 2011
$316.3K
Nov 14, 2012
Q1
2012
Jun 30, 2011
$554.6K
Aug 14, 2012
Q3
2011
Dec 31, 2010
$584.8K
Feb 14, 2012
Q2
2011
Sep 30, 2010
$399.6K
Nov 14, 2011
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2026
Dec 31, 2025
($18.90M)
Feb 12, 2026
Q3
2026
Sep 30, 2025
($19.42M)
Feb 12, 2026
Q2
2026
Sep 30, 2025
($19.42M)
Nov 13, 2025
Q2
2026
Jun 30, 2025
($15.10M)
Nov 13, 2025
Q3
2026
Jun 30, 2025
($15.10M)
Feb 12, 2026
Q1
2026
Jun 30, 2025
($15.10M)
Aug 7, 2025
Q3
2026
Dec 31, 2024
($14.09M)
Feb 12, 2026
Q3
2026
Sep 30, 2024
($12.96M)
Feb 12, 2026
Q2
2026
Sep 30, 2024
($12.96M)
Nov 13, 2025
Q2
2026
Jun 30, 2024
($10.73M)
Nov 13, 2025
Q1
2026
Jun 30, 2024
($10.73M)
Aug 7, 2025
Q3
2026
Jun 30, 2024
($10.73M)
Feb 12, 2026
Q3
2025
Dec 31, 2023
($6.35M)
Feb 13, 2025
Q2
2025
Sep 30, 2023
($6.59M)
Nov 7, 2024
Q3
2025
Sep 30, 2023
($6.59M)
Feb 13, 2025
Q1
2025
Jun 30, 2023
($6.90M)
Aug 13, 2024
Q3
2025
Jun 30, 2023
($6.90M)
Feb 13, 2025
Q2
2025
Jun 30, 2023
($6.90M)
Nov 7, 2024
Q3
2024
Dec 31, 2022
($9.76M)
Feb 13, 2024
Q3
2024
Sep 30, 2022
($17.48M)
Feb 13, 2024
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2026
Dec 31, 2025
($19.55M)
Feb 12, 2026
Q2
2026
Sep 30, 2025
($20.05M)
Nov 13, 2025
Q1
2026
Jun 30, 2025
($15.80M)
Aug 7, 2025
Q3
2026
Dec 31, 2024
($15.12M)
Feb 12, 2026
Q2
2026
Sep 30, 2024
($14.23M)
Nov 13, 2025
Q1
2026
Jun 30, 2024
($12.13M)
Aug 7, 2025
Q3
2025
Dec 31, 2023
($7.88M)
Feb 13, 2025
Q2
2025
Sep 30, 2023
($6.78M)
Nov 7, 2024
Q1
2025
Jun 30, 2023
($7.00M)
Aug 13, 2024
Q3
2024
Dec 31, 2022
($9.77M)
Feb 13, 2024
Q2
2024
Sep 30, 2022
($17.49M)
Nov 9, 2023
Q1
2024
Jun 30, 2022
($19.77M)
Aug 10, 2023
Q3
2022
Dec 31, 2021
($10.54M)
Feb 7, 2023
Q2
2022
Sep 30, 2021
($12.80M)
Nov 10, 2022
Q1
2022
Jun 30, 2021
($7.75M)
Aug 11, 2022
Q3
2022
Dec 31, 2020
($5.30M)
Feb 10, 2022
Q2
2022
Sep 30, 2020
($3.29M)
Nov 10, 2021
Q1
2021
Jun 30, 2020
($3.12M)
Aug 12, 2021
Q3
2021
Dec 31, 2019
($5.96M)
Feb 11, 2021
Q2
2021
Sep 30, 2019
($5.35M)
Nov 12, 2020